Prospective phase 1b study of Ipilimumab in patients with high risk myelodysplastic syndrome (HR-MDS) who have failed previous hypomethylating agents (HMA) therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 May 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
19 Jan 2016 New trial record
08 Dec 2015 Results of the dose escalation part (n=11) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com